In our study where NASH, instead of simple steatosis without inflammation, is induced by giving HFSD, liver expression of ChREBP significantly decreased and its expression recovered when NASH was alleviated by UDCA administration. This evidence concerns the gene MLXIPL and metabolic dysfunction-associated steatohepatitis.